Biotech Co. developing Nitric Oxide based restorative physiology 'drugs' for ischemic heart disease
Drug discovery company with a consumer products division. Currently revenue run rate for 2024 is $20–30M. Cash flow positive, debt free.
Going into Phase 3 FDA trials for Nitric Oxide “restorative physiology” drug for ischemic heart disease, plus additional pipeline. Safety was established in a related Phase 3 trial for COVID‑19.
Cash flow from Nitric Oxide‑based consumer products. Run by Dr. Nathan Bryan, PhD, who has self‑funded with the help of friends and family so far. Hundreds of millions of dollars have been generated from his Nitric Oxide product technology. He holds the only patent for a solid dose form of Nitric Oxide gas.
is owned by Bryan Therapeutics and has an experienced executive team including Dr. David Perlmutter, Dr. Bob Arnot, Susan Shaffer, Joe Hipple, Basir K. Sohail, and Susan Treadgold.
Ready to Ask For Funding for your company?
Post a Funding Request